Brief: CURACLE And Théa Announce Licensing And Collaboration Agreement For Development And Commercialization Of Orally Administered Treatment For Diabetic Macular Edema And Wet-AMD

Curacle

27/10/2021 16:51

Oct 27 (Reuters) - Curacle Co Ltd  365270.KQ :
    * CURACLE AND THÉA ANNOUNCE LICENSING AND COLLABORATION
AGREEMENT
FOR THE DEVELOPMENT AND COMMERCIALIZATION OF ORALLY ADMINISTERED
TREATMENT FOR DIABETIC MACULAR EDEMA AND WET-AMD
    * CURACLE - WILL RECEIVE AN UPFRONT PAYMENT OF $6 MILLION
AND
COULD RECEIVE UP TO AN ADDITIONAL $157.5 MILLION IN POTENTIAL
DEVELOPMENT, MILESTONES, ROYALTIES
    * CURACLE - UP TO $2 BILLION IN TOTAL PAYMENTS, INCLUDING
UPFRONT
PAYMENT, PAYMENTS FOR DEVELOPMENT, REGULATORY MILESTONES,
ROYALTIES ANTICIPATED TO BE PAID
    * CURACLE - CO WILL RETAIN MARKETING RIGHTS IN ALL ASIA
COUNTRIES
WHILE THÉA WILL HAVE MARKETING RIGHTS IN ALL OTHER COUNTRIES
AROUND WORLD

Source text for Eikon:  ID:nBw2Gz0qla 
Further company coverage:  365270.KQ 

 ((Reuters.Briefs@thomsonreuters.com;))